Olanzapine Tablets
Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.
Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.
Subpotent drug
Cause type: Wrong potency / content
Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.
Olanzapine, Orally Disintegrating Tablets, 20 mg, 30-count bottle, Rx only, Manufactured by Apotex Inc. Toronto, Ontario Canada, M9L 1T9
Drug: Olanzapine
Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.
Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.
Failed Impurities/Degradation Specifications
cGMP deviations: Temperature abuse
cGMP deviations: Temperature abuse
cGmp Deviations
Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria
Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.
Lack of Assurance of Sterility
Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.